



**Contact:**

Dr. Misha Plam

President & CEO

T: (303) 641-3669

[misha.plam@amidebio.com](mailto:misha.plam@amidebio.com)

[www.amidebio.com](http://www.amidebio.com)

**Gilad S. Gordon, M.D., M.B.A. joins the Scientific Advisory Board of AmideBio, LLC**

**BOULDER, CO, June 10, 2013** – AmideBio, LLC, a privately held biopharmaceutical company which has developed novel manufacturing processes for peptides and proteins and has under development novel Thermostable Insulin, announced today that Dr. Gilad Gordon has joined its Scientific Advisory Board. Professor Gordon brings over 20 years of scientific expertise in Private Industry and Academia, including his current position as a Clinical Associate Professor of Medicine at the University of Colorado Health Sciences Center and Principal at the ORRA Medical Consulting Group, which provides expertise in the development and implementation of Clinical trial programs in the biotechnology and pharmaceutical industry.

Dr. Gilad S. Gordon received an AB in Biochemistry from Harvard College in 1979, an MD from the HST program at Harvard Medical School and MIT in 1983, and an MBA from the University of Washington in 1988.

Dr. Gordon has a distinguished career in the field of diabetes, oncology, vaccinology, hepatology and immunology and has published numerous articles on various aspects of the diseases.

"We are very pleased to have Dr. Gordon join our Scientific Advisory Board, says Dr. Misha Plam, President and CEO of AmideBio, and he commented: "Adding Prof. Gilad Gordon as a senior advisor to AmideBio's team signals our commitment to the diabetes market. Gilad's extensive knowledge in the area of the animal and human clinical trials, especially as it relates to diabetes, is absolutely critical to us at the time when we are moving from a research and development stage to a clinical development stage company focusing on native and novel insulins".

"I am delighted to join AmideBio's Scientific Advisory Board and help the company develop their unique insulin molecules. The company's research has generated very promising molecules that could potentially help some of the world's diabetic patients. I look forward to working with this innovative and exciting organization", said Dr. Gilad Gordon.

**About AmideBio:**

AmideBio, based in Boulder, CO, is a biotechnology company founded on a unique process for the production of peptides and proteins, especially those that have been historically difficult to manufacture or produce in large quantities. The Company continues to expand its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing and internal research and development of novel biotherapeutics aimed at inflammatory and neurodegenerative diseases. The AmideBio BioPure™ process is providing the research community with some of the most pure peptide-derived products available to date, including amyloid-beta, an important protein believed to be involved with Alzheimer disease. The Company's platform offers an economical and environmentally sustainable process for large-scale production of Biosimilars, with the aim of providing patients with lower-cost medications. AmideBio's technology is the foundation for internal drug discovery and development against diseases such as Diabetes and Alzheimer's, where our BioPure™ materials have allowed for the discovery of novel targets as well as potential improvements in existing therapeutics.

- ENDS -